A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Dexamethasone (Primary)
- Indications Inflammation; Pain
- Focus Therapeutic Use
- Sponsors InSite Vision
- 01 Feb 2018 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
- 01 Feb 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2018.
- 01 Feb 2018 Status changed from not yet recruiting to recruiting.